Advert - Sanofi

• Date posted
  01 May 2015
• Sanction
  Advertisement,
• Case number/s
  AUTH/2620/7/13 - Novo Nordisk/PMCPA Director v Sanofi

For failing to comply with an undertaking by using a claim about Lyxumia (lixisenatide) in a journal supplement similar to one previously ruled in breach of the Code, Sanofi was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 9.1 - Failing to maintain high standards.

Clause 25 - Failing to comply with an undertaking.

The full case reports were published in the PMCPA May 2015 Code of Practice Review and are also available at www.pmcpa.org.uk